Literature DB >> 36269545

Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.

Sara Lomelino Pinheiro1, Joana Maciel2, Daniela Cavaco2, Ana Abrantes Figueiredo2, Inês Lemos Damásio2, Sara Donato2, João Passos3, Joana Simões-Pereira2.   

Abstract

PURPOSE: Central precocious puberty (CPP) in neurofibromatosis type 1 (NF1) occurs mainly in association with optic pathway glioma (OPG), but it can also develop in the absence of OPG. The aim of this study was to analyze the prevalence of puberty disorders in children with NF1 and its association with OPG and its location.
METHODS: A retrospective study of 45 children with NF1 (68.9% boys) followed at our center between 2008 and 2020 was conducted. A cerebral MRI scan was performed in all children. We analyzed auxological, laboratory, and imaging data of children with CPP or accelerated puberty (AP). Treatments used for CPP/AP and their effect on height were also evaluated.
RESULTS: The prevalence of puberty disorders in our cohort was 17.8% (male to female ratio of 7:1). CPP and AP were diagnosed in 8/45 (17.8%) NF1 children. Among children with puberty disorders, 5/8 (62.5%) had an OPG with chiasm involvement, 1/8 (12.5%) had an isolated optic nerve tumor, and 2/8 (25%) did not have any evidence of OPG on MRI. Fisher's exact test showed an association between CPP/AP and chiasm OPG (p = 0.025). Treatment with triptorrelin was initiated in 5/8 children, of whom four attained final predicted height.
CONCLUSION: Our study confirms the higher prevalence of CPP/AP in NF1 patients, as well as an association between chiasm OPG and puberty disorders. However, CPP/AP also occurred in the absence of OPG with an incidence of 9.1%. Comprehensive evaluation of every child with NF1 regardless of the presence of OPG is therefore essential.
© 2022. The Author(s), under exclusive licence to Hellenic Endocrine Society.

Entities:  

Keywords:  Accelerated puberty; Central precocious puberty; Gonadotropin-releasing hormone analog; Neurofibromatosis type 1; Optic pathway glioma

Year:  2022        PMID: 36269545     DOI: 10.1007/s42000-022-00411-9

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   3.419


  21 in total

Review 1.  Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1.

Authors:  M H Cnossen; E N Stam; L C Cooiman; H J Simonsz; H Stroink; A P Oranje; D J Halley; A de Goede-Bolder; M F Niermeijer; S M de Muinck Keizer-Schrama
Journal:  Pediatrics       Date:  1997-10       Impact factor: 7.124

2.  Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma
.

Authors:  Ilaria Sani; Assunta Albanese
Journal:  Horm Res Paediatr       Date:  2017-03-27       Impact factor: 2.852

3.  Neurofibromatosis type 1 and precocious puberty.

Authors:  R Virdis; M Sigorini; A Laiolo; E Lorenzetti; M E Street; A R Villani; A Donadio; F Pisani; C Terzi; L Garavelli
Journal:  J Pediatr Endocrinol Metab       Date:  2000-07       Impact factor: 1.634

Review 4.  Health Supervision for Children With Neurofibromatosis Type 1.

Authors:  David T Miller; Debra Freedenberg; Elizabeth Schorry; Nicole J Ullrich; David Viskochil; Bruce R Korf
Journal:  Pediatrics       Date:  2019-05       Impact factor: 7.124

Review 5.  Endocrine implications of neurofibromatosis 1 in childhood.

Authors:  Carla Bizzarri; Giorgia Bottaro
Journal:  Horm Res Paediatr       Date:  2015-02-05       Impact factor: 2.852

Review 6.  Neurofibromatosis type 1.

Authors:  David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson
Journal:  Nat Rev Dis Primers       Date:  2017-02-23       Impact factor: 52.329

7.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

Review 8.  Neurofibromatosis type 1: a multidisciplinary approach to care.

Authors:  Angela C Hirbe; David H Gutmann
Journal:  Lancet Neurol       Date:  2014-08       Impact factor: 44.182

9.  Precocious puberty in children with neurofibromatosis type 1.

Authors:  R Habiby; B Silverman; R Listernick; J Charrow
Journal:  J Pediatr       Date:  1995-03       Impact factor: 4.406

Review 10.  Neurofibromatosis type 1 revisited.

Authors:  Virginia C Williams; John Lucas; Michael A Babcock; David H Gutmann; Bruce Korf; Bernard L Maria
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.